Jane Street Group LLC Sells 4,707 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)

Jane Street Group LLC trimmed its stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 30.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,626 shares of the company’s stock after selling 4,707 shares during the period. Jane Street Group LLC’s holdings in ArriVent BioPharma were worth $250,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. FMR LLC grew its position in ArriVent BioPharma by 8.7% in the third quarter. FMR LLC now owns 2,119,695 shares of the company’s stock valued at $49,813,000 after acquiring an additional 169,514 shares during the period. Suvretta Capital Management LLC grew its position in ArriVent BioPharma by 7.7% in the third quarter. Suvretta Capital Management LLC now owns 1,845,162 shares of the company’s stock valued at $43,361,000 after acquiring an additional 132,459 shares during the period. Novo Holdings A S grew its position in ArriVent BioPharma by 0.4% in the third quarter. Novo Holdings A S now owns 1,505,315 shares of the company’s stock valued at $35,375,000 after acquiring an additional 5,315 shares during the period. State Street Corp grew its position in ArriVent BioPharma by 210.4% in the third quarter. State Street Corp now owns 476,809 shares of the company’s stock valued at $11,205,000 after acquiring an additional 323,186 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in ArriVent BioPharma by 153.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock valued at $4,756,000 after acquiring an additional 122,641 shares during the period. 9.48% of the stock is currently owned by institutional investors.

ArriVent BioPharma Stock Performance

Shares of AVBP stock opened at $24.88 on Friday. The stock’s fifty day moving average is $28.34 and its 200-day moving average is $25.57. ArriVent BioPharma, Inc. has a 52 week low of $14.35 and a 52 week high of $36.37.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of ArriVent BioPharma in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $36.80.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.